Pluristem Therapeutics (PSTI)'s Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONE
6/20/2013 8:49:01 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAIFA, Israel, June 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that preclinical results for its Placental eXpanded (PLX) RAD cells in the treatment of bone marrow disease have been published in peer reviewed journal PLOS ONE.
Help employers find you! Check out all the jobs and post your resume.